SELLAS Life Sciences Group (SLS) Cash & Equivalents: 2011-2024
Historic Cash & Equivalents for SELLAS Life Sciences Group (SLS) over the last 9 years, with Sep 2024 value amounting to $21.0 million.
- SELLAS Life Sciences Group's Cash & Equivalents rose 425.77% to $21.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $21.0 million, marking a year-over-year increase of 425.77%. This contributed to the annual value of $2.5 million for FY2023, which is 85.23% down from last year.
- Per SELLAS Life Sciences Group's latest filing, its Cash & Equivalents stood at $21.0 million for Q3 2024, which was up 129.92% from $9.1 million recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences Group's Cash & Equivalents registered a high of $35.3 million during Q4 2020, and its lowest value of $2.5 million during Q4 2023.
- Over the past 3 years, SELLAS Life Sciences Group's median Cash & Equivalents value was $17.1 million (recorded in 2022), while the average stood at $15.7 million.
- As far as peak fluctuations go, SELLAS Life Sciences Group's Cash & Equivalents surged by 795.72% in 2021, and later tumbled by 85.23% in 2023.
- Over the past 5 years, SELLAS Life Sciences Group's Cash & Equivalents (Quarterly) stood at $35.3 million in 2020, then crashed by 39.51% to $21.4 million in 2021, then decreased by 19.81% to $17.1 million in 2022, then tumbled by 85.23% to $2.5 million in 2023, then soared by 425.77% to $21.0 million in 2024.
- Its last three reported values are $21.0 million in Q3 2024, $9.1 million for Q2 2024, and $18.4 million during Q1 2024.